New long-term data for 89bio's NASH candidate

Positive top-line data from the blinded extension phase of its Phase IIb ENLIVEN trial evaluating treatment with pegozafermin in patients with non-alcoholic steatohepatitis (NASH) were released today by California, USA-based clinical-stage biopharmaceutical company 89bio (Nasdaq: ETNB).

Initial market reaction was positive, with 89bio’s stock up 35 pre-market, but the shares were down 2.2% at $7.73 mid-morning.

At week 48, both the 30mg weekly (QW) and 44mg every-two-week (Q2W) dosing schedules of pegozafermin demonstrated statistically significant improvements across key markers of liver health. The benefits observed at week 48 were consistent with the results observed at week 24, indicating sustained benefits over time.